BSEResult4d ago · 14 Nov 2026, 04:27 pm
Declaration of Financial results for quarter and half year ended on September 30, 2026
Orchid Pharma Ltd · 524372
✦ AI Summary▼ NegativeResults
Orchid Pharma Ltd has declared its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's net sales income for the quarter stood at ₹34,126.66 lakhs, a decrease of 14.5% from the same period last year. The company's profit before tax for the quarter was ₹2,683.69 lakhs, a decrease of 27.5% from the same period last year.
Analysis Scores
Earnings Impact4/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment3/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Orchid Pharma Ltd - 524372 - Declaration Of Financial Results For Quarter And Half Year Ended On September 30, 2026
Attachments (1)
📄pdf
Download →
4d571749-205a-4fee-b8d2-6912c220b485.pdf
View document text
OrchidPharm~W
-- A Dhanuka Group Company -------------------------------------
November 14, 2026
National Stock Exchange of India Limited, SSE Limited
Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal
Bandra (E), Mumbai-400051 Street, Fort, Mumbai-400001
Symbol: ORCHPHARMA Scrip Code: 524372
Subject: Outcome of Board Meeting - Orchid Pharma Limited ("the Company")
Dear SirjMadam,
With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of
Schedule III and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBIj
HOj49j14j14(7)2025-CFD-POD2jlj3762j2026, dated January 30, 2026, SEBI Circular no.
SEBljHOjCFDjCFD-PoD-2jCIRjPj2024j185 dated December 31, 2024 and in continuation to the prior
intimation given by the Company on November 11, 2026 for scheduling the Board Meeting, we would
like to inform you that the Board of Directors of the Company at its meeting held today i.e. November
14, 2026 (commenced at 12:00 Noon (1ST) and concluded at 04:00 P.M. (1ST) has, inter-alia,
considered and approved the Unaudited limited reviewed Standalone & Consolidated Financial Results
of the Company for quarter and half year ended on September 30, 2026 along with the auditors' limited
review reports on standalone and consolidated quarterly financial results, issued by Mjs. Singhi & Co.,
Statutory Auditors of the Company, enclosed herewith as Annexure-I.
You are requested to take the above intimations on record.
Thanking You,
For Orchid Pharm~t'"~ite '
• f£J r- <'
~(Gurgaon\=
'I...,
Ki ya 0-- -- '"l")
Co any Secretary & CO!!J,piance Officer
Mem. No. Fl0698
Encl. as above
+91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994
Registered Office: Corporate Office:
Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A,
Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India
Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.
Annexure-I
Orchid Pharma Limited
Regd Office: Plot Nos. 121 -128, 128A -133,138 -151,159 -164, SIDGO Industrial Estate, Alathur, Ghen9alpatlu District -603110, Tamil Nadu, India
Ph. +91 -44 -2744 4471 -78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com
GIN: L24222TN1992PLC022994
Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30,2026
(All amounts are in lakhs of Indian Rupees, unless otherwise stated)
S, No, Particulars Standalone financial results Consolidated financial results
For the quarter ended Six month ended For the year ended For the quarter ended Six month ended For the year ended
Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026 Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026
(Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised
(Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited)
(Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6)
Income from Operations
1 Net Sales' Income from operations 34,126.66 30,417.13 29,845.86 64,543.79 56,164.44 1,23,277.84 34126.66 30,417.13 29,845.86 64543.79 56,164.44 123277.84
2 Other Income 2,863.08 1,004.72 1,628.93 3,867.80 3,234.19 5,648.69 1775.58 182.84 1,163.85 1958.42 2,320.83 3641.83
3 Total Income (1+2) 36,989,74 31,421,85 31,474.79 68,411.59 59,398,63 1,28,926,53 35,902,24 30,599.97 31,009.71 66,502.21 58,485.27 1,26,919.67
4 Expenses
Cost of materials consumed 24,596.17 20,642,20 17,205.03 45,238.37 37,574.81 77,139.16 24596.17 20,642.20 17,205.03 45238.37 37,574.81 77139.16
Changes in inventories of raw material, work-in-progress, stock-in- (3,895.02) (272.47) 3,478.90 (4,167.49) 1,369.43 7,138.39 (3,895.02) (272.47) 3,478.90 (4,167.49) 1,369.43 7138.39
trade and finished goods
Purchases of Stock in trade 142.24 60.65 17.34 202.89 96.13 168.72 142.24 60.65 17.34 202.89 96.13 168.72
Employee benefit expenses 3,268.50 2,675.81 3,063.70 5,944.31 5,833.50 11,432.05 3140.52 2,803.79 3,144.07 5944.31 5,913.87 11765.46
Finance costs 366.12 221.23 256.81 587.35 485.29 896.15 364.33 223.02 256.81 587.35 485.29 898.43
Depreciation and amortization expense 1,131.64 1,09).16 1,070.25 2,221.80 2,123.71 4,335.60 1141.19 1,094.91 1,081.26 2236.1 2,134.72 4324.63
Other expenses 7,704.16 5,m.55 5,691.96 13,514.71 11,465.50 23,621.17 7729.12 5.782.92 5,692.10 13512.04 11,465.98 23708.71
Total EKpenses 33,313,81 30,228,13 30,783,99 63,541.94 58,948,37 1,24,731,24 33,218.55 30,335,02 30,875,51 63,553,57 59,040,23 1,25,143,50
5 Profit I (Loss) before exceptional items and tax (H) 3,675,93 1,193,72 690,80 4,869,65 450,26 4,195,29 2,683.69 264,95 134,20 2,948,64 (554,96) 1,776,17
6 Exceplional items (refer Note no.3) (733.29) (733.29)
7 Profit I (La ••) before tax (5+6) 3,675,93 1,19],72 690,80 4,869,65 450,26 3,462,00 2,683,69 264,95 134.20 2,948.64 (554,96) 1,042,88
8 TaK eKpense
Current lax
Tax adjustments of earliear years
Deferred tax (4.49) 7.23 (14.83) 2.74 (14.83) (19.16)
Total Tax Expenses (4.49) 7.23 (14.83) 2.74 (14.83) (19.16)
9 Profit I (Loss) for the period before share of profit of Associates (7·8) 3,675,93 1,193,/2 690.80 4,869.65 450,26 3,462,00 2,688.18 257.72 149,03 2,945,90 (540,13) 1,062,04
Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 (Contd ... )
S. No. Particulars Standalone financial results Consolidated financial results
For the quarter ended Six month ended Forthe For the quarter ended Six month ended Forthe
year ended year ended
Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sap 30, 2025 March 31, 2026 Sep 30, 2026 June 30, 2026 Sep 30, 2025 Sep 30, 2026 Sep 30, 2025 March 31, 2026
(Unaudited) (Unaudited) Revised (Unaudited) Revised Revised (Unaudited) (Unaudited) Revised (Unaudited) Revised Revised
(Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) (Audited)
(Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6) (Refer Note 6)
10 Profit I (loss) for the period before share of profit of Associates 3,675.93 1,193.72 690.80 4,869.65 450.26 3,462.00 2,688.18 257.72 149.03 2,945.90 (540.13) 1,062.04
11 Add: Share of Profit/ (loss) of Associates 171.23 64.72 (23B.B7) 235.95 (11B.93) (66.13)
12 Profit I (Loss) for the period (10+11) 3,675.93 1,193.72 690.80 4,869.65 450.26 3,462.00 2,859.41 322.44 (89.84) 3,181.85 (659.06) 995.91
13 Other comprehensive income, net of income tax
a) (i) items that will not be reclassified to profit or loss (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 (30.70) 0.64 (39.45) (30.06) (54.93) 131.76
(ii) income tax relating to items that will not be
reclassified to profit or loss
b) (i) items that will be reclassified to profit or loss
(ii) income tax relating to items that will be reclassified
to profit or loss
Total other comprehensive Incomel (loss), net of Income tax (30.70) 0.64 (39.45) (30.06) (54.93) 131.76 (30.70) 0.64 (39.45) (30.06) (54.93) 131.76
14 Total comprehensive incomel (Loss) for the period (12+13) 3,645.23 1,194.36 651.35 4,839.59 395.33 3,593.76 2,828.71 323.08 (129.29) 3,151.79 (713.99) 1,127.67 I~
15 Paid·up equity share capital 5.988.52 5.988.52 5,988.52 5,988.52 5,988.52 5.988.52 5.988.52 5,988.52 5,988.52 5.988.52 5,988.52 5.988.52
(Including Shares pending allotment on account of Merger)
Other Equity 1,58,679.07 1.50,442.18
Face value per share (Rs) 10.00 10.00 10.00 10.00 10.00 10.00 10.00 to.OO 10.00 10.00 10.00 10.00
16 Earnings per equity share ":
-Basic (Rs.) 6.14 1.99 1.15 8.13 0.75 5.78 4.77 0.54 (0.15) 5.31 (1.10) 1.66
. Diluted (Rs.) 6.14 1.99 1.15 8.13 0.75 5.78 4.77 0.54 (0.15) 5.31 (1.10) 1.66
• I EPS for the quarters are not annualised
c,~1 cI c.
: " : t. 0 .
V (r ) '.U -
[Showing first 8,000 characters — download PDF for full document]